<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857671</url>
  </required_header>
  <id_info>
    <org_study_id>90953</org_study_id>
    <secondary_id>2019-001385-16</secondary_id>
    <nct_id>NCT04857671</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A in Frequent and Chronic Tension-type Headache</brief_title>
  <acronym>BACT</acronym>
  <official_title>Botulinum Toxin A in Frequent and Chronic Tension-type Headache: A Double Blind, Randomized, Placebo-controlled Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Nord-Trøndelag HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sandvika Nevrosenter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Nord-Trøndelag HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic tension-type headache (CTTH) is an underestimated disabling condition that affects a&#xD;
      large number of patients. The treatment options for both episodic tension-type headaches, but&#xD;
      especially CTTH are few. Poor long-term effects of existing treatment for CTTH (Sarotex,&#xD;
      SSRIs, physiotherapy) are reported. Patients with CTTH also have a high risk of developing&#xD;
      drug overdose headache (MOH). Non-drug treatments with physiotherapy/ alternative medicine&#xD;
      also show poor long-term effects. And literature reviews shoes that there is surprisingly&#xD;
      little research on CTTH. Some small clinical trials report a good effect of treatment with&#xD;
      botulinum toxin A in CTTH, but larger controlled trials are needed to confirm or deny this.&#xD;
&#xD;
      We will study effect of treatment with botulinum toxin A in CTTH in BACT study, and we will&#xD;
      include participants with both frequent and chronic TTH with 10 or more headache days per&#xD;
      month.&#xD;
&#xD;
      If BACT outcomes are positive, it will open a possibillity for a new treatment for TTH&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The screening/baseline period with headache diary will be 4 weeks long. Then will all participants be randomized into 2 groups for 2 periods in cross over method. They will get two injections during this study: one injection with botulinum toxin (Botox) and one with placebo (NaCl 0,9% Braun). After each in injections there will be a 12 weeks long follow up period, where participants continue to keep a headache diary and register adverse events. Participant will also have a 4 weeks long wash-out period after the first treatment period. A study nurse or researcher will call participants 4 times during the trial to promote headache diary and check for adverse events.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>days with headache per month</measure>
    <time_frame>12 weeks</time_frame>
    <description>'during the active period'</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum pain intensity</measure>
    <time_frame>36 weeks</time_frame>
    <description>on a 0-10 numerical rating scale (NRS) 'during the active period'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of headache hours per day</measure>
    <time_frame>36 weeks</time_frame>
    <description>'during the active period'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with intake of pain-killers per month</measure>
    <time_frame>36 weeks</time_frame>
    <description>'during the active period'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score on EQ-5D-5L</measure>
    <time_frame>36 weeks</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>36 weeks</time_frame>
    <description>scale 7-points - (very much better) to 7 (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean monthly headache days from baseline</measure>
    <time_frame>36 weeks</time_frame>
    <description>during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tension-Type Headache</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin A injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin A (Botox)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isotone saline water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A in saline water</intervention_name>
    <description>150 Allergan units Botulinum toxin A in a total of 3 ml sodium chloride (NaCl) 0,9% Braun.&#xD;
5 IU of Botox per injection point (0,1ml); in total 150 IU per 30 injections points.</description>
    <arm_group_label>Botulinum toxin A injections</arm_group_label>
    <arm_group_label>placebo injections</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotone saline water</intervention_name>
    <description>3ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 30 injections points</description>
    <arm_group_label>Botulinum toxin A injections</arm_group_label>
    <arm_group_label>placebo injections</arm_group_label>
    <other_name>Sodium chloride solution</other_name>
    <other_name>NaCl solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  frequent or chronic tension type headache according to ICHD-3 with 10 or more headache&#xD;
             days per month&#xD;
&#xD;
          -  Headache history of minimum one year.&#xD;
&#xD;
          -  Previously failed treatment with intolerable side-effects to or contra-indications to&#xD;
             at least one tension-type headache prophylactic drug&#xD;
&#xD;
          -  Subject agrees to maintain current preventive headache medication regimens (no change&#xD;
             in type, frequency, or dose) during the whole study period&#xD;
&#xD;
          -  In case of women of childbearing potential (WOCBP) they have to be using highly&#xD;
             effective contraception. Such methods include: combined (oestrogen and progestogen&#xD;
             containing) hormonal contraception associated with inhibition of ovulation (oral,&#xD;
             intravaginal or transdermal); progestogen-only hormonal contraception associated with&#xD;
             inhibition of ovulation (oral, injectable or implantable); intrauterine device (IUD);&#xD;
             intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised&#xD;
             partner; sexual abstinence. This group of patients should not be using other drugs&#xD;
             that might interact and reduce the efficacy of the used anticonceptive drug. WOCBP is&#xD;
             defined as fertile women, following menarche and until becoming post-menopausal unless&#xD;
             permanently sterile. Permanent sterilisation methods include: hysterectomy, bilateral&#xD;
             salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no&#xD;
             menses for 12 months without an alternative medical cause. Ability to understand study&#xD;
             procedures and to comply with them for the entire length of the study. WOCBP will have&#xD;
             to agree to take a pregnancy test before the injection with the study drug&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  migraine with more than 1 migraine day per month&#xD;
&#xD;
          -  other forms of primary or secondary headaches; including medication overuse headache&#xD;
             (MOH)&#xD;
&#xD;
          -  Change in type, dosage or dose frequency of preventive headache or sleep medications &lt;&#xD;
             1 months prior to inclusion&#xD;
&#xD;
          -  Previous exposure at any time to any botulinum toxin serotype&#xD;
&#xD;
          -  Pregnancy, breastfeeding or planned pregnancy&#xD;
&#xD;
          -  Inadequate contraceptive use. Women of childbearing potential (WOCBP) who do not use&#xD;
             highly effective contraception (HEC) will be excluded&#xD;
&#xD;
          -  diseases that are contraindications for use of BoNT-A (Myasthenia gravis,&#xD;
             Eaton-Lambert syndrome, amyotrophic lateral sclerosis, other diseases interfering with&#xD;
             neuromuscular function) or allergy to BoNT-A, or treatment with drugs affecting the&#xD;
             neuromuscular junction&#xD;
&#xD;
          -  currently having an active local infection at the sites of injection based on present&#xD;
             symptoms.&#xD;
&#xD;
          -  diagnosed with any major infectious processes such as osteomyelitis, or primary or&#xD;
             secondary malignancies involving the face that have been active or required treatment&#xD;
             in the past 6 months.&#xD;
&#xD;
          -  Serious psychiatric disease that may affect study in opinion of study investigator&#xD;
&#xD;
          -  Other severe chronical pain conditions&#xD;
&#xD;
          -  Ongoing abuse of alcohol or illicit drugs in the opinion of the investigator&#xD;
&#xD;
          -  Participating in another trial that might affect the current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norunn Hanssen Hestvik</last_name>
    <role>Study Director</role>
    <affiliation>Clinic for Medicine and rehabilitation, Nord Trøndelag Trust HNT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Devik, MD</last_name>
    <phone>+47 98833255</phone>
    <email>kristina.devik@helse-nordtrondelag.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erling Tronvik, MD PhD</last_name>
    <email>erling.tronvik@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Namsos Sykehus</name>
      <address>
        <city>Namsos</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristina Devik, MD PhD</last_name>
      <email>kristina.devik@helse-nordtrondelag.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Botulinum toxins, type A</keyword>
  <keyword>Injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tension-Type Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

